Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.96 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL5973704 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3388 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536412 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5984073 | 1.00 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14840776 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL177947 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2282827 | 0.98 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.98 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749180 | 0.96 | FDPS (0.89) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661257-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | Bilgic, Mahmut (TR) | 2013-11-13 | — | — | EP | claimed |
| EP-2561877-A1 | A Composition containing a Bisphosphonic Acid in combination with Vitamin D | Mylan Pharmaceuticals ULC (CA) | 2013-02-27 | — | — | EP | claimed |
| WO-2012093978-A1 | EFFERVESCENT BISPHOSPHONATE FORMULATIONS | BILGIC MAHMUT (TR) | 2012-07-12 | — | — | WO | claimed |
| US-20100179110-A1 | Composition Containing a Bisphosphonic Acid in Combination with Vitamin D | GENPHARM INC. (CA) | 2010-07-15 | — | — | US | claimed |
| EP-2124963-A1 | A COMPOSITION CONTAINING A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D | Genpharm ULC (CA) | 2009-12-02 | — | — | EP | claimed |
| US-7611722-B2 | Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-03 | — | — | US | claimed |
| EP-1465606-A4 | DOSAGE FORM WITH A CORE TABLET OF ACTIVE INGREDIENT SHEATHED IN A COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR MATERIAL, AND PROCESS AND TOOLING FOR PRODUCING IT | TEVA PHARMA (IL) | 2009-04-22 | — | — | EP | claimed |
| WO-2008074144-A1 | A COMPOSITION CONTAINING A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D | GENPHARM ULC (CA) | 2008-06-26 | — | — | WO | claimed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | claimed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1296657-A1 | COMPOSITION AND DOSAGE FORM FOR DELAYED GASTRIC RELEASE OF ALENDRONATE AND/OR OTHER BIS-PHOSPHONATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-02 | — | — | EP | claimed |
| WO-2003007916-A1 | DOSAGE FORMS FOR IMMEDIATE GASTRIC RELEASE OF A CALCIUM TRANSPORT STIMULATOR COUPLED WITH DELAYED GASTRIC RELEASE OF A BIS-PHOSPHONATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-30 | — | — | WO | claimed |
| US-6476006-B2 | COMPACT FORM FOR ORAL ADMINISTERING; BONE DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-11-05 | — | — | US | claimed |
| US-20020015733-A1 | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | TEVA PHARMACEUTICAL USA, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002000204-A1 | COMPOSITION AND DOSAGE FORM FOR DELAYED GASTRIC RELEASE OF ALENDRONATE AND/OR OTHER BIS-PHOSPHONATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-03 | — | — | WO | claimed |
| EP-1107974-A4 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2001-09-26 | — | — | EP | claimed |
| US-6281381-B1 | CRYSTAL STRUCTURE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-08-28 | — | — | US | claimed |
| EP-1107974-A1 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012517-A9 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2000-07-13 | — | — | WO | claimed |
| WO-2000012517-A1 | NOVEL HYDRATE FORMS OF ALENDRONATE SODIUM, PROCESSES FOR MANUFACTURE THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | FDPS 1326/4885PDE3A 539/4885LMNA 1068/4885 |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | FDPS 1286/4885PDE3A 618/4885LMNA 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.